{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T01:16:19Z","timestamp":1794359779832,"version":"4.9.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,5,15]],"date-time":"2018-05-15T00:00:00Z","timestamp":1526342400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,5,15]],"date-time":"2018-05-15T00:00:00Z","timestamp":1526342400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Nipah and Hendra viruses are recently emerged bat-borne paramyxoviruses (genus\n                    <jats:italic>Henipavirus<\/jats:italic>\n                    ) causing severe encephalitis and respiratory disease in humans with fatality rates ranging from 40\u201375%. Despite the severe pathogenicity of these viruses and their pandemic potential, no therapeutics or vaccines are currently approved for use in humans. Favipiravir (T-705) is a purine analogue antiviral approved for use in Japan against emerging influenza strains; and several phase 2 and 3 clinical trials are ongoing in the United States and Europe. Favipiravir has demonstrated efficacy against a broad spectrum of RNA viruses, including members of the\n                    <jats:italic>Paramyxoviridae<\/jats:italic>\n                    ,\n                    <jats:italic>Filoviridae<\/jats:italic>\n                    ,\n                    <jats:italic>Arenaviridae families<\/jats:italic>\n                    , and the\n                    <jats:italic>Bunyavirales<\/jats:italic>\n                    order. We now demonstrate that favipiravir has potent antiviral activity against henipaviruses.\n                    <jats:italic>In vitro<\/jats:italic>\n                    , favipiravir inhibited Nipah and Hendra virus replication and transcription at micromolar concentrations. In the Syrian hamster model, either twice daily oral or once daily subcutaneous administration of favipiravir for 14 days fully protected animals challenged with a lethal dose of Nipah virus. This first successful treatment of henipavirus infection\n                    <jats:italic>in vivo<\/jats:italic>\n                    with a small molecule drug suggests that favipiravir should be further evaluated as an antiviral treatment option for henipavirus infections.\n                  <\/jats:p>","DOI":"10.1038\/s41598-018-25780-3","type":"journal-article","created":{"date-parts":[[2018,5,9]],"date-time":"2018-05-09T11:03:36Z","timestamp":1525863816000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":172,"title":["Favipiravir (T-705) protects against Nipah virus infection in the hamster model"],"prefix":"10.1038","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7847-7376","authenticated-orcid":false,"given":"Brian E.","family":"Dawes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birte","family":"Kalveram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8318-2783","authenticated-orcid":false,"given":"Tetsuro","family":"Ikegami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry","family":"Juelich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer K.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8916-2230","authenticated-orcid":false,"given":"Arnold","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benhur","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Komeno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yousuke","family":"Furuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander N.","family":"Freiberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,5,15]]},"reference":[{"key":"25780_CR1","doi-asserted-by":"crossref","first-page":"642","DOI":"10.5694\/j.1326-5377.1995.tb126050.x","volume":"162","author":"LA Selvey","year":"1995","unstructured":"Selvey, L. A. et al. Infection of humans and horses by a newly described morbillivirus. Med J Aust 162, 642\u2013645 (1995).","journal-title":"Med J Aust"},{"key":"25780_CR2","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1126\/science.288.5470.1432","volume":"288","author":"KB Chua","year":"2000","unstructured":"Chua, K. B. et al. Nipah virus: a recently emergent deadly paramyxovirus. Science 288, 1432\u20131435 (2000).","journal-title":"Science"},{"key":"25780_CR3","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1111\/bpa.12278","volume":"25","author":"KC Ong","year":"2015","unstructured":"Ong, K. C. & Wong, K. T. Henipavirus Encephalitis: Recent Developments and Advances. Brain Pathol 25, 605\u2013613 (2015).","journal-title":"Brain Pathol"},{"key":"25780_CR4","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.antiviral.2012.05.008","volume":"95","author":"B Rockx","year":"2012","unstructured":"Rockx, B., Winegar, R. & Freiberg, A. N. Recent progress in henipavirus research: molecular biology, genetic diversity, animal models. Antiviral Res 95, 135\u2013149 (2012).","journal-title":"Antiviral Res"},{"key":"25780_CR5","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1016\/S0140-6736(99)04299-3","volume":"354","author":"KB Chua","year":"1999","unstructured":"Chua, K. B. et al. Fatal encephalitis due to Nipah virus among pig-farmers in Malaysia. Lancet 354, 1257\u20131259 (1999).","journal-title":"Lancet"},{"key":"25780_CR6","doi-asserted-by":"publisher","first-page":"328","DOI":"10.3201\/eid2102.141433","volume":"21","author":"PK Ching","year":"2015","unstructured":"Ching, P. K. et al. Outbreak of henipavirus infection, Philippines, 2014. Emerg Infect Dis 21, 328\u2013331 (2015).","journal-title":"Emerg Infect Dis"},{"key":"25780_CR7","doi-asserted-by":"publisher","first-page":"e6367","DOI":"10.1371\/journal.pone.0006367","volume":"4","author":"JF Drexler","year":"2009","unstructured":"Drexler, J. F. et al. Henipavirus RNA in African bats. PLoS One 4, e6367, https:\/\/doi.org\/10.1371\/journal.pone.0006367 (2009).","journal-title":"PLoS One"},{"key":"25780_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms6342","volume":"5","author":"O Pernet","year":"2014","unstructured":"Pernet, O. et al. Evidence for henipavirus spillover into human populations in Africa. Nat Commun 5, 5342, https:\/\/doi.org\/10.1038\/ncomms6342 (2014).","journal-title":"Nat Commun"},{"key":"25780_CR9","doi-asserted-by":"publisher","first-page":"987","DOI":"10.3201\/eid0809.010515","volume":"8","author":"JG Olson","year":"2002","unstructured":"Olson, J. G. et al. Antibodies to Nipah-like virus in bats (Pteropus lylei), Cambodia. Emerg Infect Dis 8, 987\u2013988 (2002).","journal-title":"Emerg Infect Dis"},{"key":"25780_CR10","doi-asserted-by":"crossref","unstructured":"Young, P. L. et al. Serologic evidence for the presence in Pteropus bats of a paramyxovirus related to equine morbillivirus. Emerg Infect Dis 2 (1996).","DOI":"10.3201\/eid0203.960315"},{"key":"25780_CR11","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.antiviral.2013.07.011","volume":"100","author":"SP Luby","year":"2013","unstructured":"Luby, S. P. The pandemic potential of Nipah virus. Antiviral Res 100, 38\u201343 (2013).","journal-title":"Antiviral Res"},{"key":"25780_CR12","doi-asserted-by":"publisher","first-page":"4624","DOI":"10.1128\/JVI.00005-14","volume":"88","author":"CE Mire","year":"2014","unstructured":"Mire, C. E. et al. A recombinant Hendra virus G glycoprotein subunit vaccine protects nonhuman primates against Hendra virus challenge. J Virol 88, 4624\u20134631 (2014).","journal-title":"J Virol"},{"key":"25780_CR13","first-page":"125","volume":"135","author":"CC Broder","year":"2013","unstructured":"Broder, C. C. Passive immunization and active vaccination against Hendra and Nipah viruses. Dev Biol (Basel) 135, 125\u2013138 (2013).","journal-title":"Dev Biol (Basel)"},{"key":"25780_CR14","unstructured":"Cartwright, D. Hendra virus vaccine trial reveals no ill-effects, http:\/\/www.smh.com.au\/queensland\/hendra-virus-vaccine-trial-reveals-no-illeffects-20160627-gpt9nk.html (2016)."},{"key":"25780_CR15","doi-asserted-by":"publisher","first-page":"242ra282","DOI":"10.1126\/scitranslmed.3008929","volume":"6","author":"TW Geisbert","year":"2014","unstructured":"Geisbert, T. W. et al. Therapeutic treatment of Nipah virus infection in nonhuman primates with a neutralizing human monoclonal antibody. Sci Transl Med 6, 242ra282, https:\/\/doi.org\/10.1126\/scitranslmed.3008929 (2014).","journal-title":"Sci Transl Med"},{"key":"25780_CR16","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1002\/ana.1062","volume":"49","author":"HT Chong","year":"2001","unstructured":"Chong, H. T. et al. Treatment of acute Nipah encephalitis with ribavirin. Ann Neurol 49, 810\u2013813 (2001).","journal-title":"Ann Neurol"},{"key":"25780_CR17","doi-asserted-by":"publisher","first-page":"11979","DOI":"10.1128\/JVI.01847-09","volume":"83","author":"J Pallister","year":"2009","unstructured":"Pallister, J. et al. Chloroquine administration does not prevent Nipah virus infection and disease in ferrets. J Virol 83, 11979\u201311982 (2009).","journal-title":"J Virol"},{"key":"25780_CR18","doi-asserted-by":"publisher","first-page":"9831","DOI":"10.1128\/JVI.01163-10","volume":"84","author":"B Rockx","year":"2010","unstructured":"Rockx, B. et al. A novel model of lethal Hendra virus infection in African green monkeys and the effectiveness of ribavirin treatment. J Virol 84, 9831\u20139839 (2010).","journal-title":"J Virol"},{"key":"25780_CR19","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1099\/vir.0.017269-0","volume":"91","author":"AN Freiberg","year":"2010","unstructured":"Freiberg, A. N., Worthy, M. N., Lee, B. & Holbrook, M. R. Combined chloroquine and ribavirin treatment does not prevent death in a hamster model of Nipah and Hendra virus infection. J Gen Virol 91, 765\u2013772 (2010).","journal-title":"J Gen Virol"},{"key":"25780_CR20","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1128\/AAC.50.5.1768-1772.2006","volume":"50","author":"MC Georges-Courbot","year":"2006","unstructured":"Georges-Courbot, M. C. et al. Poly(I)-poly(C12U) but not ribavirin prevents death in a hamster model of Nipah virus infection. Antimicrob Agents Chemother 50, 1768\u20131772 (2006).","journal-title":"Antimicrob Agents Chemother"},{"key":"25780_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/srep43395","volume":"7","author":"MK Lo","year":"2017","unstructured":"Lo, M. K. et al. GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses. Sci Rep 7, 43395, https:\/\/doi.org\/10.1038\/srep43395 (2017).","journal-title":"Sci Rep"},{"key":"25780_CR22","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1021\/acs.jmedchem.6b01594","volume":"60","author":"D Siegel","year":"2017","unstructured":"Siegel, D. et al. Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses. J Med Chem 60, 1648\u20131661 (2017).","journal-title":"J Med Chem"},{"key":"25780_CR23","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.antiviral.2017.06.011","volume":"144","author":"AL Hotard","year":"2017","unstructured":"Hotard, A. L., He, B., Nichol, S. T., Spiropoulou, C. F. & Lo, M. K. 4\u2032-Azidocytidine (R1479) inhibits henipaviruses and other paramyxoviruses with high potency. Antiviral Res 144, 147\u2013152 (2017).","journal-title":"Antiviral Res"},{"key":"25780_CR24","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.antiviral.2013.09.015","volume":"100","author":"Y Furuta","year":"2013","unstructured":"Furuta, Y. et al. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res 100, 446\u2013454 (2013).","journal-title":"Antiviral Res"},{"key":"25780_CR25","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1128\/AAC.46.4.977-981.2002","volume":"46","author":"Y Furuta","year":"2002","unstructured":"Furuta, Y. et al. In vitro and in vivo activities of anti-influenza virus compound T-705. Antimicrob Agents Chemother 46, 977\u2013981 (2002).","journal-title":"Antimicrob Agents Chemother"},{"key":"25780_CR26","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/irv.12446","volume":"11","author":"P Koszalka","year":"2017","unstructured":"Koszalka, P., Tilmanis, D. & Hurt, A. C. Influenza antivirals currently in late-phase clinical trial. Influenza Other Respir Viruses 11, 240\u2013246 (2017).","journal-title":"Influenza Other Respir Viruses"},{"key":"25780_CR27","doi-asserted-by":"publisher","first-page":"5202","DOI":"10.1128\/AAC.00649-13","volume":"57","author":"H Sangawa","year":"2013","unstructured":"Sangawa, H. et al. Mechanism of action of T-705 ribosyl triphosphate against influenza virus RNA polymerase. Antimicrob Agents Chemother 57, 5202\u20135208 (2013).","journal-title":"Antimicrob Agents Chemother"},{"key":"25780_CR28","doi-asserted-by":"publisher","first-page":"2770","DOI":"10.1093\/jac\/dku209","volume":"69","author":"L Delang","year":"2014","unstructured":"Delang, L. et al. Mutations in the chikungunya virus non-structural proteins cause resistance to favipiravir (T-705), a broad-spectrum antiviral. J Antimicrob Chemother 69, 2770\u20132784 (2014).","journal-title":"J Antimicrob Chemother"},{"key":"25780_CR29","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1093\/infdis\/jiv586","volume":"213","author":"K Yamada","year":"2016","unstructured":"Yamada, K., Noguchi, K., Komeno, T., Furuta, Y. & Nishizono, A. Efficacy of Favipiravir (T-705) in Rabies Postexposure Prophylaxis. J Infect Dis 213, 1253\u20131261 (2016).","journal-title":"J Infect Dis"},{"key":"25780_CR30","doi-asserted-by":"publisher","first-page":"e1001967","DOI":"10.1371\/journal.pmed.1001967","volume":"13","author":"D Sissoko","year":"2016","unstructured":"Sissoko, D. et al. Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea. PLoS Med 13, e1001967, https:\/\/doi.org\/10.1371\/journal.pmed.1001967 (2016).","journal-title":"PLoS Med"},{"key":"25780_CR31","doi-asserted-by":"publisher","first-page":"4620","DOI":"10.1128\/AAC.00709-16","volume":"60","author":"D Jochmans","year":"2016","unstructured":"Jochmans, D. et al. Antiviral Activity of Favipiravir (T-705) against a Broad Range of Paramyxoviruses In Vitro and against Human Metapneumovirus in Hamsters. Antimicrob Agents Chemother 60, 4620\u20134629 (2016).","journal-title":"Antimicrob Agents Chemother"},{"key":"25780_CR32","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1128\/JVI.02583-14","volume":"89","author":"T Yun","year":"2015","unstructured":"Yun, T. et al. Efficient reverse genetics reveals genetic determinants of budding and fusogenic differences between Nipah and Hendra viruses and enables real-time monitoring of viral spread in small animal models of henipavirus infection. J Virol 89, 1242\u20131253 (2015).","journal-title":"J Virol"},{"key":"25780_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/srep14775","volume":"5","author":"D Safronetz","year":"2015","unstructured":"Safronetz, D. et al. The broad-spectrum antiviral favipiravir protects guinea pigs from lethal Lassa virus infection post-disease onset. Sci Rep 5, 14775, https:\/\/doi.org\/10.1038\/srep14775 (2015).","journal-title":"Sci Rep"},{"key":"25780_CR34","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.antiviral.2014.01.016","volume":"104","author":"D Scharton","year":"2014","unstructured":"Scharton, D. et al. Favipiravir (T-705) protects against peracute Rift Valley fever virus infection and reduces delayed-onset neurologic disease observed with ribavirin treatment. Antiviral Res 104, 84\u201392 (2014).","journal-title":"Antiviral Res"},{"key":"25780_CR35","doi-asserted-by":"publisher","first-page":"e2804","DOI":"10.1371\/journal.pntd.0002804","volume":"8","author":"L Oestereich","year":"2014","unstructured":"Oestereich, L. et al. Evaluation of antiviral efficacy of ribavirin, arbidol, and T-705 (favipiravir) in a mouse model for Crimean-Congo hemorrhagic fever. PLoS Negl Trop Dis 8, e2804, https:\/\/doi.org\/10.1371\/journal.pntd.0002804 (2014).","journal-title":"PLoS Negl Trop Dis"},{"key":"25780_CR36","doi-asserted-by":"crossref","unstructured":"Gowen, B. B. et al. Alterations in favipiravir (T-705) pharmacokinetics and biodistribution in a hamster model of viral hemorrhagic fever. Antiviral Res (2015).","DOI":"10.1016\/j.antiviral.2015.07.003"},{"key":"25780_CR37","doi-asserted-by":"publisher","first-page":"e2614","DOI":"10.1371\/journal.pntd.0002614","volume":"7","author":"BB Gowen","year":"2013","unstructured":"Gowen, B. B. et al. Favipiravir (T-705) inhibits Junin virus infection and reduces mortality in a guinea pig model of Argentine hemorrhagic fever. PLoS Negl Trop Dis 7, e2614, https:\/\/doi.org\/10.1371\/journal.pntd.0002614 (2013).","journal-title":"PLoS Negl Trop Dis"},{"key":"25780_CR38","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.antiviral.2014.02.014","volume":"105","author":"L Oestereich","year":"2014","unstructured":"Oestereich, L. et al. Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model. Antiviral Res 105, 17\u201321 (2014).","journal-title":"Antiviral Res"},{"key":"25780_CR39","doi-asserted-by":"publisher","unstructured":"Tani, H. et al. Efficacy of T-705 (Favipiravir) in the Treatment of Infections with Lethal Severe Fever with Thrombocytopenia Syndrome Virus. mSphere 1, https:\/\/doi.org\/10.1128\/mSphere.00061-15 (2016).","DOI":"10.1128\/mSphere.00061-15"},{"key":"25780_CR40","doi-asserted-by":"publisher","first-page":"2637","DOI":"10.1016\/j.vaccine.2014.02.087","volume":"32","author":"BL DeBuysscher","year":"2014","unstructured":"DeBuysscher, B. L., Scott, D., Marzi, A., Prescott, J. & Feldmann, H. Single-dose live-attenuated Nipah virus vaccines confer complete protection by eliciting antibodies directed against surface glycoproteins. Vaccine 32, 2637\u20132644 (2014).","journal-title":"Vaccine"},{"key":"25780_CR41","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.antiviral.2013.10.012","volume":"101","author":"MK Lo","year":"2014","unstructured":"Lo, M. K. et al. Single-dose replication-defective VSV-based Nipah virus vaccines provide protection from lethal challenge in Syrian hamsters. Antiviral Res 101, 26\u201329 (2014).","journal-title":"Antiviral Res"},{"key":"25780_CR42","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1128\/JVI.80.4.1972-1978.2006","volume":"80","author":"V Guillaume","year":"2006","unstructured":"Guillaume, V. et al. Antibody prophylaxis and therapy against Nipah virus infection in hamsters. J Virol 80, 1972\u20131978 (2006).","journal-title":"J Virol"},{"key":"25780_CR43","doi-asserted-by":"publisher","first-page":"7658","DOI":"10.1128\/JVI.00473-11","volume":"85","author":"B Rockx","year":"2011","unstructured":"Rockx, B. et al. Clinical outcome of henipavirus infection in hamsters is determined by the route and dose of infection. J Virol 85, 7658\u20137671 (2011).","journal-title":"J Virol"},{"key":"25780_CR44","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1016\/S0002-9440(10)63569-9","volume":"163","author":"KT Wong","year":"2003","unstructured":"Wong, K. T. et al. A golden hamster model for human acute Nipah virus infection. Am J Pathol 163, 2127\u20132137 (2003).","journal-title":"Am J Pathol"},{"key":"25780_CR45","doi-asserted-by":"publisher","first-page":"e1001168","DOI":"10.1371\/journal.ppat.1001168","volume":"6","author":"M Porotto","year":"2010","unstructured":"Porotto, M. et al. Inhibition of Nipah virus infection in vivo: targeting an early stage of paramyxovirus fusion activation during viral entry. PLoS Pathog 6, e1001168, https:\/\/doi.org\/10.1371\/journal.ppat.1001168 (2010).","journal-title":"PLoS Pathog"},{"key":"25780_CR46","doi-asserted-by":"crossref","unstructured":"Park, A. et al. Optimized P2A for reporter gene insertion into Nipah virus results in efficient ribosomal skipping and wild-type lethality. J Gen Virol 97 (2016).","DOI":"10.1099\/jgv.0.000405"},{"key":"25780_CR47","doi-asserted-by":"publisher","unstructured":"Sidwell, R. W. et al. Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice. Antimicrob Agents Chemother 51, 845\u2013851 [pii] https:\/\/doi.org\/10.1128\/AAC.01051-06 (2007).","DOI":"10.1128\/AAC.01051-06"},{"key":"25780_CR48","doi-asserted-by":"publisher","first-page":"e1000642","DOI":"10.1371\/journal.ppat.1000642","volume":"5","author":"KN Bossart","year":"2009","unstructured":"Bossart, K. N. et al. A neutralizing human monoclonal antibody protects against lethal disease in a new ferret model of acute nipah virus infection. PLoS Pathog 5, e1000642, https:\/\/doi.org\/10.1371\/journal.ppat.1000642 (2009).","journal-title":"PLoS Pathog"},{"key":"25780_CR49","doi-asserted-by":"publisher","first-page":"105ra103","DOI":"10.1126\/scitranslmed.3002901","volume":"3","author":"KN Bossart","year":"2011","unstructured":"Bossart, K. N. et al. A neutralizing human monoclonal antibody protects african green monkeys from hendra virus challenge. Sci Transl Med 3, 105ra103, https:\/\/doi.org\/10.1126\/scitranslmed.3002901 (2011).","journal-title":"Sci Transl Med"},{"key":"25780_CR50","doi-asserted-by":"publisher","first-page":"e36833","DOI":"10.1371\/journal.pone.0036833","volume":"7","author":"A Pessi","year":"2012","unstructured":"Pessi, A. et al. A general strategy to endow natural fusion-protein-derived peptides with potent antiviral activity. PLoS One 7, e36833, https:\/\/doi.org\/10.1371\/journal.pone.0036833 (2012).","journal-title":"PLoS One"},{"key":"25780_CR51","doi-asserted-by":"publisher","first-page":"e3725","DOI":"10.1371\/journal.pone.0003725","volume":"3","author":"BB Gowen","year":"2008","unstructured":"Gowen, B. B. et al. Treatment of late stage disease in a model of arenaviral hemorrhagic fever: T-705 efficacy and reduced toxicity suggests an alternative to ribavirin. PLoS One 3, e3725, https:\/\/doi.org\/10.1371\/journal.pone.0003725 (2008).","journal-title":"PLoS One"},{"key":"25780_CR52","doi-asserted-by":"publisher","unstructured":"Gowen, B. B. et al. Modeling Severe Fever with Thrombocytopenia Syndrome Virus Infection in Golden Syrian Hamsters: Importance of STAT2 in Preventing Disease and Effective Treatment with Favipiravir. J Virol 91, https:\/\/doi.org\/10.1128\/JVI.01942-16 (2017).","DOI":"10.1128\/JVI.01942-16"},{"key":"25780_CR53","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1073\/pnas.0909603107","volume":"107","author":"M Kiso","year":"2010","unstructured":"Kiso, M. et al. T-705 (favipiravir) activity against lethal H5N1 influenza A viruses. Proc Natl Acad Sci USA 107, 882\u2013887 (2010).","journal-title":"Proc Natl Acad Sci USA"},{"key":"25780_CR54","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/S0140-6736(96)06162-4","volume":"349","author":"JD O\u2019Sullivan","year":"1997","unstructured":"O\u2019Sullivan, J. D. et al. Fatal encephalitis due to novel paramyxovirus transmitted from horses. Lancet 349, 93\u201395 (1997).","journal-title":"Lancet"},{"key":"25780_CR55","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1002\/ana.10212","volume":"51","author":"CT Tan","year":"2002","unstructured":"Tan, C. T. et al. Relapsed and late-onset Nipah encephalitis. Ann Neurol 51, 703\u2013708 (2002).","journal-title":"Ann Neurol"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-25780-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-25780-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-25780-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T00:19:29Z","timestamp":1671581969000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-25780-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,15]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["25780"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-25780-3","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.733248434.793565842","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,15]]},"assertion":[{"value":"17 November 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"T.K. and Y.F. are employees of the Toyama Chemical Co., Ltd., the manufacturer of favipiravir. All other authors declare that no competing interests exist.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"7604"}}